Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O P Smith

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Irish Journal of Medical Science|May 8, 2002
Thermolabile methylenetetrahydrofolate reductase (C677T): frequency in the Irish populationL A Mynett-Johnson, C Keenan, I L Black, et al.
Leukemia|February 20, 2003
Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicinC M Zwaan, D Reinhardt, H Jürgens, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2025
Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based studyA Trama, E E Geerdes, E Demuru, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Irish Journal of Medical Science|May 8, 2002
Thermolabile methylenetetrahydrofolate reductase (C677T): frequency in the Irish populationL A Mynett-Johnson, C Keenan, I L Black, et al.
Leukemia|February 20, 2003
Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicinC M Zwaan, D Reinhardt, H Jürgens, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2025
Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based studyA Trama, E E Geerdes, E Demuru, et al.
Pageof 8